Global Alert: 32% of Eating Disorder Patients Use Weight Loss Injections Without Medical Supervision
A groundbreaking study published in JAMA Psychiatry reveals that one in three patients with eating disorders has used GLP-1 agonists like semaglutide and tirzepatide. Researchers from the University of Louisville warn about the lack of evaluation protocols and the growing risk of obtaining these medications through unregulated online providers.
